BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28210881)

  • 21. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
    Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
    Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
    Suh JH; Schrock AB; Johnson A; Lipson D; Gay LM; Ramkissoon S; Vergilio JA; Elvin JA; Shakir A; Ruehlman P; Reckamp KL; Ou SI; Ross JS; Stephens PJ; Miller VA; Ali SM
    Oncologist; 2018 Jul; 23(7):776-781. PubMed ID: 29540602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
    Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2015 Jul; 152(2):305-12. PubMed ID: 26093648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
    Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
    Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions.
    Sim Y; Ng GXP; Ng CCY; Rajasegaran V; Wong SF; Liu W; Guan P; Nagarajan S; Ng WY; Thike AA; Lim JCT; Nasir NDBM; Tan VKM; Madhukumar P; Yong WS; Wong CY; Tan BKT; Ong KW; Teh BT; Tan PH
    BMC Med Genomics; 2019 Oct; 12(1):142. PubMed ID: 31647027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
    Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
    Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
    Patel RR; Ramkissoon SH; Ross J; Weintraub L
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic landscapes of breast fibroepithelial tumors.
    Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
    Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant phyllodes tumour with lymph node metastasis: a diagnostic conundrum resolved by next generation DNA sequencing.
    Schwartz CJ; Krings G; Chen YY
    Histopathology; 2024 Jan; 84(2):409-411. PubMed ID: 37706238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.
    Jacob JM; Ferry EK; Gay LM; Elvin JA; Vergilio JA; Ramkissoon S; Severson E; Necchi A; Killian JK; Ali SM; Schrock AB; Liu NW; Chung J; Miller VA; Stephens PJ; Welsh A; Corona RJ; Ross JS; Bratslavsky G
    J Urol; 2019 Mar; 201(3):541-548. PubMed ID: 30291913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative genomic analysis of primary tumors and metastases in breast cancer.
    Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
    Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
    Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS
    Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic characteristics of two breast malignant phyllodes tumors during pregnancy and lactation identified through whole-exome sequencing.
    Lei T; Shen M; Deng X; Shi Y; Peng Y; Wang H; Chen T
    Orphanet J Rare Dis; 2022 Oct; 17(1):382. PubMed ID: 36271373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.
    Jardim DL; Conley A; Subbiah V
    Orphanet J Rare Dis; 2013 Jul; 8():112. PubMed ID: 23895135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.
    Liang WS; Vergilio JA; Salhia B; Huang HJ; Oki Y; Garrido-Laguna I; Park H; Westin JR; Meric-Bernstam F; Fabrizio D; Miller VA; Stephens PJ; Fanale MA; Ross JS; Janku F
    Oncologist; 2019 Feb; 24(2):219-228. PubMed ID: 30108156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
    Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
    Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.
    Ross JS; Gay LM; Wang K; Vergilio JA; Suh J; Ramkissoon S; Somerset H; Johnson JM; Russell J; Ali S; Schrock AB; Fabrizio D; Frampton G; Miller V; Stephens PJ; Elvin JA; Bowles DW
    Ann Oncol; 2017 Oct; 28(10):2539-2546. PubMed ID: 28961851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups.
    Tan WJ; Lai JC; Thike AA; Lim JC; Tan SY; Koh VC; Lim TH; Bay BH; Tan MH; Tan PH
    Breast Cancer Res Treat; 2014 Jun; 145(3):635-45. PubMed ID: 24831776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.